Search Results for: Global Type 2 Diabetes Market
Articles
ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care October 6, 2015
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
Unilife Introduces World's First Instant Patch Pump for Insulin August 3, 2015
York, PA. – July 29, 2015. Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and...Selecta Biosciences Makes Two Major Announcements May 18, 2015
Selecta Biosciences, Inc. recently announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option...SPECIAL FEATURE - Outsourcing Formulation & Manufacturing Development: Using Data & Unique Approaches to Solve Solubility Issues, Target Profiles & Customize Products March 31, 2015
Contributor Cindy H. Dubin finds that CMOs are embracing development projects in an effort to establish longer-lasting partnerships with their pharma and biotech clients. These contract developers are deploying innovative techniques aimed at improving solubility and fast-tracking products to market.
Sanofi & MannKind Announce Afrezza, the Only Inhaled Insulin, Now Available in the US February 4, 2015
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by...SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
SPECIAL FEATURE - Patients & Physicians Desire Transdermal, Topical & Subcutaneous Delivery July 9, 2014
Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.
Transition Therapeutics to Receive up to $30.8 Million June 10, 2014
Transition Therapeutics Inc. recently announced that Jack W. Schuler , Larry N. Feinberg, Oracle Investment Management, certain Transition Board members,...Novozymes' Half-Life Extension Technology Reaches Landmark Milestone Approval April 28, 2014
The US FDA has granted marketing approval to GlaxoSmithKline's new type 2 diabetes drug, branded Tanzeum in the US and...Novozymes’ VELTIS Technology Used in GlaxoSmithKline Drug Approved in Europe April 7, 2014
Novozymes Biopharma DK A/S recently announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the...Oramed Pharmaceuticals Receives Patent for the Oral Delivery of Insulin November 26, 2013
Oramed Pharmaceuticals Inc. recently announced that the European Patent Office has allowed the company's patent for its invention, titled Methods...SOLID DOSAGE FORMS - Better Treatments Through Innovative Solid Oral Drug Release Technologies October 16, 2013
Steven Hamlen, MBA, and Nicholas Johnson, PhD, MBA, discuss recent technology innovations in controlled-release solid oral dose functions and forms as well as more established methods for altering release profiles of molecules, and provide a real-world case study in which applying alternative formulation technology significantly improved an existing therapy and delivered patient and payer benefits.
Patients & Physicians Express Desire to Switch to Transdermal Drug Delivery July 18, 2013
The $82-billion US drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening FDA...Valeritas Closes $100 Million Financing June 9, 2013
Valeritas recently announced they have closed a structured debt financing with Capital Royalty L.P., which provides Valeritas with up to...J&J Expects More Than 10 NDAs May 24, 2013
Johnson & Johnson recently announced it is developing what could eventually be game-changing treatments for depression and pain, and it's...Arena Pharmaceuticals Receives $65 Million From Eisai May 14, 2013
Arena Pharmaceuticals, Inc. recently announced that the Office of the Federal Register filed for public inspection the US Drug Enforcement...SPECIAL REPORT - Prefilled Syringes & Parenteral Contract Manufacturing: Improving for Flexibility & Customization April 30, 2013
Special Feature: Contributor Cindy H. Dubin speaks with prefilled syringe manufacturers as well as contract parenteral manufacturers who share their thoughts about the delivery challenges associated with high-viscous, high-volume formulations.
Biodel Completes Phase II Enrollment in Clinical Trial of Ultra-Rapid-Acting Insulin April 1, 2013
Biodel Inc. recently announced the completion of patient enrollment in a Phase II clinical study of ultra-rapid-acting prandial insulin candidate...VIVUS Announces $110-Million Synthetic Capped Royalty Financing April 1, 2013
VIVUS, Inc. recently announced that it has entered into a $110-million non-equity financing with an investment fund managed by Pharmakon...Novozymes Biopharma Announces Agreement With EpiVax February 11, 2013
Novozymes Biopharma recently announced a collaborative research agreement with Rhode Island-based biotech company, EpiVax, Inc. to help further the...Issues
June 2011
When Deals Work - & When They Don't: Large Pharma Strategies for Off-Loading Shuttered Capacity Derek G. Hennecke continues with...
